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Abstract
The pathogenesis of Bronchiolitis Obliterans Syndrome (BOS), the main clinical phenotype
of chronic lung allograft dysfunction, is poorly understood. Recent studies suggest that epi-
genetic regulation of microRNAs might play a role in its development. In this paper we pres-
ent the application of a complex computational pipeline to perform enrichment analysis of
miRNAs in pathways applied to the study of BOS. The analysis considered the full set of
miRNAs annotated in miRBase (version 21), and applied a sequence of filtering approaches
and statistical analyses to reduce this set and to score the candidate miRNAs according to
their potential involvement in BOS development. Dysregulation of two of the selected candi-
date miRNAs–miR-34a andmiR-21 –was clearly shown in in-situ hybridization (ISH) on five
explanted human BOS lungs and on a rat model of acute and chronic lung rejection, thus
definitely identifyingmiR-34a andmiR-21 as pathogenic factors in BOS and confirming the
effectiveness of the computational pipeline.
Introduction
Since James Hardy performed the first human lung transplantation (LTx) in 1963, LTx has
become an accepted therapeutic option for carefully selected patients with an end-stage lung
disease. The number of LTx has increased steadily over the last two decades and currently
more than 3,000 lung transplantation procedures are performed yearly worldwide. LTx mainly
intends to improve survival. However, long-term survival is hampered by the development of
chronic lung allograft dysfunction (occurring in up to 50% of patients in the 5th post-trans-
plant year), whose main clinical manifestation is represented by Bronchiolitis Obliterans Syn-
drome (BOS) [1]. As a consequence, long-term survival after LTx remains worse than that
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achieved for other solid organ transplantations (median overall adult survival, 5.6 years accord-
ing to the latest ISHLT figures https://www.ishlt.org/registries/quarterlyDataReport.asp).
Histologically, BOS is characterized by Bronchiolitis Obliterans (BO), i.e. patchy submu-
cosal fibrosis involving the respiratory bronchioles, resulting in near-total or total occlusion
of the airway lumen. BOS is the final outcome of an array of injuries to the airway epithe-
lium and extracellular matrix including alloimmune-specific reactions, autoimmune
responses and non-specific inflammatory insults (infections and gastro-esophageal reflux).
The exact pathogenesis of BOS is still largely unknown. It is believed that an insult to the
epithelium leads to an inflammatory response that might be associated with a shift from tol-
erance to immune activation, which in turn induces severe neutrophilic airway inflamma-
tion [2]. Activated neutrophils can further damage the epithelium by releasing reactive
oxygen species, chemokines, alarmins and metalloproteinases (MMPs). This inflammatory
phase is ultimately followed by a fibro-proliferative phase leading to transition from epithe-
lial to mesenchymal cells, proliferation of myofibrocytes, and collagen deposition. Even if
the pathogenesis of BOS following LTx has not been clarified completely, recent studies sug-
gest that epigenetic regulations involving microRNAs may play an important role in its
development [3][4][5].
MicroRNAs (miRNAs) are the most studied class of small non-coding RNAs, containing
approximately 20 nucleotides. They regulate post transcriptional gene expression by binding to
target messenger RNAs (mRNAs) and inducing either inhibition of translation or mRNA deg-
radation [6][7][8][9]. It is thought that miRNAs regulate approximately 30% of the human
protein-coding genome [6]. They control the expression of genes involved in several key bio-
logical processes such as cell development, stem cell proliferation, division and differentiation,
regulation of immunity, apoptosis, cell signaling and metabolism, etc. [6][8][9][10][11]. More-
over, aberrant expression of miRNAs has been associated with several pathological processes,
such as cancer [9][12][13], metabolic disorders [14], autoimmune diseases [11] and acute cel-
lular rejection following kidney transplantation [15]. Clarifying the role of miRNAs in disease
pathogenesis is therefore crucial.
There are two approaches to the study of the role of miRNAs in diseases. The traditional
"omics" approach assesses a wide panel of factors on plasma/tissue samples and identifies those
significantly (2-fold to 10-fold) dysregulated in disease samples with respect to controls. In the
other, computational algorithms are used to perform a preliminary exploratory analysis to nar-
row down number of factors to test in the subsequent wet-lab validation phase. These
approaches, however, do not always provide information on the specific cellular site of expres-
sion, which is far more relevant than absolute expression levels.
In this paper, we implemented a pure computational pipeline to perform enrichment analy-
sis of miRNAs in pathways involved in BOS pathogenesis. This enabled us to identify a limited
panel of candidate miRNAs with potential involvement in BOS development. Unlike in other
approaches, such as GSEA [16] and miTEA [17], we did not rely on expression profiles data to
perform our analysis, but instead we integrated and processed information from a large set of
different repositories, thus performing a pure exploratory analysis to pinpoint which specific
wet-lab experiments would be most useful.
Preliminary validation of the selection of miRNAs was attained both through literature
analysis during the computational phase; and by subsequent in situ hybridization experiments
onmiR-34a andmiR-21, two of the resulting candidate miRNAs. Interestingly, hybridization
experiments clearly showed, for the first time, dysregulation of these two miRNAs at cellular
level in BOS tissue samples. This provided important insights into their role in the pathogene-
sis of BOS, opening perspectives for further mechanistic and therapeutic studies.
Computational Analysis of miRNA Involvement in BOS
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Materials and Methods
Fig 1 shows the experimental workflow followed in this study. Green boxes identify the compu-
tational pipeline implemented to identify the candidate miRNAs involved in BOS, whereas
blue boxes identify wet-lab activities performed for validation of the results. The computational
pipeline implements a set of data fusion engines able to automatically collect and integrate
Fig 1. Computational workflow followed to identify relevant miRNAs (green and orange blocks). Two selected miRNAs (i.e.,miR-34a andmiR-21)
obtained from the computational analysis were then validated in wet lab experiments (blue boxes).
doi:10.1371/journal.pone.0161771.g001
Computational Analysis of miRNA Involvement in BOS
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omics information from a set of public repositories (orange boxes in Fig 1). Collected data are
then analyzed through a set of statistical tests to score the analyzed miRNAs. The source code
and the related data implementing the computation pipeline described in Fig 1 are publicly
available through the BOS-miRNA-Enrichment repository on GitHub at https://github.com/
sysbio-polito/BOS-miRNA-Enrichment.
Identification of the set of relevant pathways
The proposed computational workflow starts from the identification of a set of relevant path-
ways behind key biological processes involved in the development of BOS. Several pathway
repositories collect curated information on a large number of biological networks. These can be
explored and analyzed for high-level systemic analysis [18, 19]. In this paper we resorted to the
list of networks available in the KEGG database (http://www.genome.jp/kegg/pathway.html).
KEGG is unique in its focus on and coverage of yeast, mouse, and human metabolic and signal-
ing pathways, with a set of more than 200 networks for Homo sapiens [20]. To support the
pathways identification process, we developed the automatic literature mining workflow,
reported in Fig 2, whose code is available in the “1-literature-mining” folder of the BOS-miR-
NA-Enrichment repository on GitHub.
The workflow starts with a search of the available literature using NCBI E-utilities [21], with
the three queries (Q1-Q3) reported in Fig 2. Each query contained associations of key terms
related to BOS enabling the retrieval of a collection of relevant publications. This set of publica-
tions was further refined by including custom studies not directly identified by the three que-
ries but known to be relevant to BOS. We used the NCBI E-utilities again on the new list to
identify related genes annotated in the selected publications. Finally, starting from the list of
genes identified, we used KEGG API to search for KEGG pathways annotated for the identified
genes.
The automatic literature mining process identified a list of 51 pathways (see the “Results”
folder of the BOS-miRNA-Enrichment repository on GitHub) that were then manually
reviewed and filtered. This step was important to remove false positive pathways that might
have been introduced by the automatic literature mining process or to add pathways eluded in
the automatic search. This resulted in the list of 39 pathways reported in the S1 Table. Each
pathway was assigned to one out of three classes, depending on their assumed relevance in the
pathogenesis of BOS. Class A identified highly relevant pathways behind very specific biologi-
cal processes related to the pathogenesis of BOS. Class B identified pathways relevant in more
general processes compared to class A, but still important in the development of the disease.
Finally, class C pathways are very general pathways with reduced specificity in the development
of BOS. Assignment to the different classes and review of the pathways list was carried out by
three researchers expert in BOS pathogenesis: a clinician (FM), a pathologist (PM) and a genet-
ist (ER). This information was necessary to weigh the contribution of any given pathway dur-
ing computational analysis, in order to avoid bias due to low specificity of pathways within the
targeted pathology.
Pathway extension to include transcription factors
Starting from the identified set of relevant pathways for BOS development, our computational
workflow was used to search for possible interactions between miRNAs and genes involved in
the different pathways. While direct interactions between miRNAs and their target genes can
be retrieved from publicly available repositories, as explained in the sections that follow, it is
well known that miRNA-mediated post-transcriptional regulation of selected genes can also
act indirectly by translational repression or mRNA degradation of their transcription factors
Computational Analysis of miRNA Involvement in BOS
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Fig 2. Pathway selection process. The NCBI E-Utilities Application Programming Interface (API) and KEGG API were used to mine the available
literature and to identify a preliminary set of relevant pathways connected to BOS pathogenesis.
doi:10.1371/journal.pone.0161771.g002
Computational Analysis of miRNA Involvement in BOS
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(TFs) [10][22][23][24]. Considering these indirect interactions is therefore very important
when analyzing miRNA-pathway interactions. However, pathway repositories, such as KEGG,
usually lack systematic information regarding the TF of each gene involved in a given regula-
tory network.
To take into account TF-mediated miRNA regulations, we developed a php script able to
process the KEGGMarkup Language (KGML) description of a pathway and systematically
integrate TF information for each described gene (see Fig 1). TF information is retrieved by
connecting to the RESTful APIs provided by TargetMine [25]. For a given gene, the “Upstream
Transcription Factors Template Query” (Targetmine) enables the retrieval of all upstream reg-
ulatory genes (TFs) from the AMADEUS [26][27] and ORegAnno [28] libraries of transcrip-
tion factors-target gene relations. By applying this computational step, each pathway
considered was extended to systematically include the TFs for all the genes involved. The
source code used to process each pathway is available in the “2-Pathway-Processing” folder of
the BOS-miRNA-Enrichment repository on GitHub.
Identification of miRNA
Our computational selection of candidate miRNAs involved in BOS development started from
the full list of miRNAs annotated in miRBase (version 21 published on June 2014) [29]. MiR-
Base is a searchable database of published miRNA sequences. Version 21 of miRBase was
exported in its SQL format and a list of 1870 miRNA precursor sequences for Homo sapiens
species representing our initial list of miRNAs was extracted.
In order to perform the miRNA target enrichment analysis, we first retrieved miRNA target
information for each miRNA contained in our initial list. miRNA target information was
retrieved by automatically mining the TargetHUB repository with a php script (see Fig 1). Tar-
getHUB provides a programmer-friendly interface to aggregate multiple repositories of
miRNA target genes with a uniform set of APIs [30]. The TargetHUB interface allows users to
query information from four different databases: miRTarBase [31], TargetScan [32], PicTar
[33], and miRanda [34]. TargetHUB uses miRBase Version 18 nomenclature. Because the
nomenclature for miRNAs is not completely standard across different versions of miRBase,
names of those miRNAs whose names in miRBase (version 21) match miRBase (version 18)
remained unchanged. miRNAs that had no matching identifier were manually mapped resort-
ing to the name change logs available in miRBase.
In our study, we analyzed each miRNA considering two different sets of miRNA targets:
• Targets obtained by querying TargetHUB with results collected from the miRTarBase data-
base referred to as Validated miRNA Targets (VMTs). MiRTarBase is known to collect infor-
mation related to experimentally validated miRNA targets [35].
• Targets obtained by querying TargetHUB for results present in at least one of the five avail-
able repositories. These are referred to as Computational miRNA Targets (CMTs) since they
contain a large set of computationally-inferred information.
VMTs were the main focus of this research and were used as the main source of information
to identify the set of miRNAs to be tested in the laboratory. Nevertheless, CMTs were also of
interest because they enlarged the scope of the analysis and allowed the formulation of explor-
atory predictions on miRNAs, to be tested in future experiments. In the remainder of this
paper we will use the general term miRNA targets to identify both VMTs and CMTs. The set of
scripts used to perform this computational step is available in the “3-Mirna-Processing” folder
of the BOS-miRNA-Enrichment repository on GitHub.
Computational Analysis of miRNA Involvement in BOS
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miRNAs enrichment analysis
To identify relevant miRNAs in BOS development we performed enrichment analysis of
miRNA gene targets in the selected pathways for each of the 1870 considered miRNAs. This
analysis allowed us to rank miRNAs based on their overall enrichment in the selected path-
ways. This information was used to skim the initial list of miRNAs, identifying a reduced panel
with potential higher involvement in the pathogenesis of BOS.
Making use of a combination of php and R scripts, we constructed a 2x2 contingency matrix
for each miRNA-pathway pair, as shown in Fig 3. Np+ represents the number of genes in the
pathway targeted by the miRNA. It is obtained by intersecting information on miRNA targets
with the list of genes and TFs for the pathway. Np- represents the number of non-targeted
genes in the pathway, while Nm+ represents the total number of miRNA targets. Finally, Nm-
represents the total number of genes not targeted by the miRNA.
Fig 3. miRNA vs. pathway contingency table.Np+: number of targeted genes in the pathway, Np-: number of non-targeted genes in the
pathway, Nm+: number of total targets of the miRNA, Nm-: number of total genes not targeted by the miRNA.
doi:10.1371/journal.pone.0161771.g003
Computational Analysis of miRNA Involvement in BOS
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To perform a fair analysis, Nm- was computed by merging the list of targets of all consid-
ered miRNAs and subtracting the targets of the miRNA under evaluation; and Np- was com-
puted by excluding those genes in the pathway that had never been annotated as a miRNA
target in the considered database.
For each miRNA-pathway pair we applied a one-tailed Fisher's exact test to compute the
enrichment of the miRNA targets in the selected pathway [36][37]. The one-tailed test for a
2x2 case computes p-values directly using the hypergeometric distribution. It provides exact
probabilities and is appropriate for small number statistics [37]. By means of the Fisher's test
we were able to test, for each miRNA-pathway pair, the hypothesis of a miRNA having its tar-
get genes enriched in a given pathway.
Finally, significance levels computed for each miRNA when paired with each pathway were
combined together in order to test the significance of the miRNA enrichment over the joint set
of pathways. First, false discovery rate (FDR) was applied to the p-values for each miRNA-
pathway pair, in order to correct for multiple-hypothesis testing, thus implementing the cor-
rection as previously described in [38]. Second, corrected p-values were combined by applying
the modified Lancaster's method proposed in [39]. Lancaster's method is a meta-analysis algo-
rithm, which can be used to combine the results of more than one test bearing upon the same
hypothesis. Compared to the Fisher's combined probability test widely used in other enrich-
ment studies to combine p-values [40], Lancaster's method enables the introduction of weight-
ing functions for the combined p-values. Weighting functions allowed for the incorporation of
prior biological information in the analysis leading to more meaningful results. In particular,
in our study, p-values were weighted according to the relevance class of the related pathway,
reported in the S1 Table. Class A pathways where weighted the highest (2), equal to the tradi-
tional Fisher's combined probability test [39]. Class B pathways were weighted 1 to account for
reduced relevance in the analysis and, finally, class C pathways were weighted 0.5. Finally, the
modified Lancaster's method previously proposed in [39] and applied in this study accounts
for correlation among the single tests. This is important in our setup since pathways often
share common sets of genes. Traditional Fisher's combined probability tests are based on the
independence assumption, which does not hold in our setup. Based on the result of the com-
bined p-value test, we were able to assign to each miRNA a single enrichment significance
level. Only highly significant enriched miRNAs (p<0.01) were retained in the final reduced
panel of miRNAs as candidates for laboratory analysis.
As an example, Fig 4 reports a sample of the computations performed in the analysis of a
single miRNA (miR-34a) using VMTs. The analysis starts from acquisition of the list of
miRNA targets and ends with the computation of an enrichment score for the miRNA in the
considered set of pathways. The source code for the scripts used to perform this analysis is
available in the “4-Enrichment-Analisys” folder of the BOS-miRNA-Enrichment repository on
GitHub.
Final filtering
Finally, the scored list of miRNAs was filtered according to two different criteria. First we
selected the miRNAs identified as being expressed in relevant tissue samples. This step is
important to focus on the miRNAs specifically active in the target tissue. To perform this oper-
ation, we consulted mimiRNA, a database of miRNA expression across different tissues and
cell lines [41]. mimiRNA incorporates a sample classification algorithm that groups identical
miRNA or mRNA experiments from separate sources. This enables mimiRNA to provide reli-
able expression profiles and to discover functional relations between miRNAs and mRNAs
such as miRNA targets. The mimiRNA database for the selected tissues was downloaded and
Computational Analysis of miRNA Involvement in BOS
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processed by means of a php script in order to extract a list of miRNAs significantly expressed
in lung tissues and in the following cells involved in specific immunity and non-specific inflam-
mation in BOS:
• Lung tissues;
• B lymphocytes;
• Natural killer lymphocytes;
• Monocytes;
• Dendritic cells;
• Granulocytes; and
• A549 (A549 cells derive from a peripheral well-differentiated lung adenocarcinomas, which
retain several features of mature deep airway epithelium, and are therefore frequently used in
experimental studies as a "model" of human bronchiolo-alveolar epithelium).
The second step was to select intragenic miRNA co-expressed by genes or transcription fac-
tors in the selected pathways. To perform this operation, we consulted the miRIAD Intragenic
Microrna database [42]. Each gene and transcription factor belonging to the considered path-
ways was automatically queried on miRIAD to identify if it potentially hosts an intragenic
miRNA. Intragenic miRNAs selected in this step are likely to be co-expressed with their host
genes [43] and therefore have a good chance of being expressed within biological processes
involved in the pathogenesis of BOS.
The full list of 349 miRNAs selected along with the tissue or cell in which they are expressed
is reported in the S1 File, while the code for the script used to perform the filtering is available
in the “3-Mirna-Processing” folder of the BOS-miRNA-Enrichment repository on GitHub.
Wet lab experiments
ISH for two candidate miRNAs (miR-34a andmiR-21) was performed on formalin-fixed/par-
affin-embedded samples of normal human and rat lungs, lung explants of BOS patients and rat
models of acute and chronic lung rejection (outbred CD SPF/VAF), and on mesenchymal cells
obtained from bronchoalveolar lavage (BAL) of lung recipients. The specimens were collected
from the University of Padua and Foundation IRCSS San Matteo/University of Pavia Pathol-
ogy Units. The study to develop an animal model of obliterans bronchiolitis was approved by
the Research Ethics Committee of University of Padua (Protocol n. 0004959: Approval of
informed consent from patients for tissue storage and research use. Date of approval: 27/01/
2011. Project n. 23/2014: 244 Development of an animal model of obliterans bronchiolitis.
Date of approval: 245 13/10/2014). All procedures used in this study were conformed to the
rules and principles of the 2010/63/EU Directive. Lung explants of BOS patients were collected
from IRCSS San Matteo/University of Pavia Pathology Units. The study was approved by
Fig 4. Example of step by step processing of a single miRNA using VMTs. (1) miR-34a, used as an
example in the figure, is queried on TargetHUB to obtain its list of targets (VMTs); (2) The list of targets is
intersected with the list of genes for each considered pathway to obtain a matrix showing howmany targets
belong to each pathway; (3) The matrix built during step 2, together with the total gene count for each
pathway, is used to construct a set of contingency tables (one for each miRNA/pathway pair) as shown in Fig
3; (4) For each miRNA/pathway pair, the related contingency table is used to perform a one-tailed Fisher’s
exact test to compute the enrichment of the miRNA targets in the pathway, obtaining a p-value that measures
the significance of the test; and (5) p-values obtained for each miRNA/pathway pair are combined into a
single significance score by the application of the modified Lancaster's method proposed in [39].
doi:10.1371/journal.pone.0161771.g004
Computational Analysis of miRNA Involvement in BOS
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Pavia Area Ethics Committee of Foundation IRCCS San Matteo (Protocol n. 20140003328: Iso-
lation and characterization of mesenchymal cells obtained from bronchoalveolar lavage of lung
recipients. Date of approval: 28/07/2014). Written informed consents of patients have been
obtained before explant. Additional information regarding the Research Ethics Committee are
provided in S2 File.
miR-34a and miR-21 are double-DIG labeled miRCURY LNA1microRNA Detection
Probes and have the sequences 5'-ACAACCAGCTAAGACACTGCCA-3', and 5'-TCAACAT
CAGTCTGATAAGCTA-3' respectively. U6 and a scramble probe were used respectively as
positive and negative controls. All probes were purchased from Exiqon.
ISH was performed according to the manufacturer's protocol provided by Exiqon (Exiqon,
Vedbaek, Denmark) [44] with slight modifications described below.
ISH experiments were performed on tissue sections and mesenchymal cells (MCs) isolated
from BAL of BOS patients and cultured on Lab-Tek1II Chamber SlidesTM (Thermo Scien-
tific) according to [45]. Normal skin fibroblasts (NHDF-cor; PromoCell GmbH, Heidelberg
Germany) were used as control. Six micron thick unstained tissue sections were deparaffinized
and digested with Proteinase-K (15 μg/mL) for 10' at 37°C using an Abbott Molecular StatSpin
ThermoBrite Hybridizer System (Dako hybridizer). Hybridization with 40nMmiR-21 probe,
1nM U6 probe and 20nM scramble probe was carried out at 50°C for 60 min. FormiR-34a, a
less-abundantly expressed miRNA, 100nM labeled probe was used and hybridization was car-
ried out at 37°C for 20h. Furthermore, to preventmiR-34a release and extra-tissutal diffusion
during hybridization, an additional miRNA fixation step, using 1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide, was added on tissue sections to anchor miRNAs into the protein matrix
[46]. Stringent washes were carried out in 5X SSC, 1X SSC and 0.2X SSC at 55°C. The digoxi-
genins were then recognized by a specific anti-DIG antibody, directly conjugated with the
enzyme Alkaline Phosphatase and the cells were stained with NCIP/NBT chromogenic
substrate.
Images of miRNA signals were captured by an Olympus BX41 microscope equipped for
conventional bright light and epifluorescence microscopy and connected to an image acquisi-
tion software (Cell F, Olympus). Consecutive unstained sections were stained with Movat pen-
tachrome stain for connective tissue to highlight tissue morphology and connective tissue
components, and immunoreacted with anti-actin HHF35 monoclonal antibody (Dako,
Glostrup, DE) on the Dako Omnis autostainer platform to confirm the myofibroblast location
of positive ISH signals. All reactions were analyzed under the light microscope and reviewed
blindly by two skilled pathologists (PM and FC).
Results
Panel of miRNA involved in the pathogenesis of BOS
Figs 5 and 6 report the main results obtained by the computational pipeline described in Fig 1.
The analysis performed with VMTs (Fig 5) identified a set of 29 miRNAs, out of the 349
miRNAs considered in the initial dataset, whose targets were significantly enriched (p-
value<0.01) in the selected pathways. miRNAs were ranked according to the significance of
their enrichment in the pathways. This result enabled us to narrow down considerably the set
of candidate miRNAs to be investigated in the laboratory. The complete list of scores for the
miRNAs considered is presented in the S1 File.
Limiting the analysis to VMTs might have biased the results due to the limited amount of
information available in the miRTarBase repository. To enlarge the exploratory scope of our
study, we also submitted CMTs to analysis, and we were able to identify another ranked set of
174 miRNAs (Fig 6) whose targets (both computational and validated) were significantly
Computational Analysis of miRNA Involvement in BOS
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enriched (p-value<0.01) in the set of selected pathways. The list produced in this case was, of
course, larger than the one presented in Fig 5, since, unlike VMTs, CMTs are available for all
considered miRNAs. This enabled us to enlarge the spectrum of possible interactions between
miRNAs and pathways, and to account for miRNAs that might have escaped our attention.
Fig 5. Ranked list of miRNAsmost significantly enriched in BOS-related pathways (p<0.01) considering VMTs. Results are plotted using a
-log(p-value).
doi:10.1371/journal.pone.0161771.g005
Fig 6. Ranked list of the top 30miRNAsmost significantly enriched in BOS-related pathways (p<0.01) considering CMTs. Results are
plotted using a -log(p-value).
doi:10.1371/journal.pone.0161771.g006
Computational Analysis of miRNA Involvement in BOS
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Nevertheless, the information obtained in this second analysis must be considered carefully. It
is well known that computational methods for miRNA target analysis are not highly accurate
and often generate a high number of false positives [47]. The complete list of scores for the con-
sidered miRNAs obtained with this second analysis is also available in the S1 File while Fig 6
shows the 30 top ranked miRNAs in this list.
Finally, in order to complete the analysis, we performed a random control experiment by
applying the computational pipeline to a random selection of 39 pathways from KEGG.
Interestingly, the number of significantly enriched miRNA selected by the computational
flow dropped to only 5 in the analysis performed with VMTs (Fig 7) and to only 2 miRNAs for
the analysis performed with CMTs (Fig 8). This provides a good indication that the selected
miRNAs depend on the considered set of BOS-related pathways. However, it is interesting to
note that in both cases (VMTs and CMTs), the miRNAs identified in the random control were
also reported in the list of miRNAs related to BOS. This result was not unexpected. First of all,
the reader may note that the score obtained for this random control (-log(p-value)) is higher
than the corresponding score assigned when considering BOS related pathways. This means
reduced enrichment in the selected set of random pathways. Second, the presence of these miR-
NAs in the random control is probably an indication that they might be related to more general
cell proliferation/differentiation mechanisms relevant in several disease processes. While they
can still be found dysregulated in BOS patients (for this reason they have not been removed
from the lists reported in Figs 5 and 6) they are less specific for the target disease.
ISH results
In order to validate the results of the computational analysis, we analyzed specific miRNA
expression profiles in a set of lung tissue samples obtained from animals and patients with BOS
and in mesenchymal cells from BAL of lung recipients, and compared these with results
obtained from normal controls. Information regarding the Research Ethics Committee is pro-
vided in the S2 File. The ISH approach was preferred to qRT-PCR, since it not only provides
Fig 7. Ranked list of miRNAs highly significantly enriched in a set of 39 randomly selected pathways (p<0.01) considering VMTs. Results
are plotted using a -log(p-value).
doi:10.1371/journal.pone.0161771.g007
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evidence of local dysregulation but also allows morphological correlations and highlights the
expression profiles in different cell types (inflammatory cells like macrophages or lymphocytes,
normal or reactive epithelial cells, endothelial cells, and, finally, fibroblasts). Specifically, BO
lesions involve a small proportion of lung tissue and therefore the quantitative approach could
miss significant differences in expression levels occurring in limited, although extremely dis-
ease-specific, tissue components.
To choose the first two miRNAs to be validated by wet-lab experiments we firstly focused
on those factors present in both lists shown in Figs 5 and 6, but not identified in the random
control set of miRNAs. The factors present in both lists were: let-7a,miR-34a,miR-21 and
miR-9 family. The let-7a andmiR-9miRNAs were also among those identified in the random
control set, and we excluded them as their dysregulation might be related to a more general cell
proliferation/differentiation mechanism relevant in several disease processes, but not specifi-
cally related to BOS. Moreover,miR-21 andmiR-34a had not yet been described in BOS in pre-
vious human studies. Given these premises, we selectedmiR-34a, the top-ranked miRNA in
Fig 5 (VMTs) andmiR-21, as candidate miRNAs for ISH analysis.
Our preliminary results documented the dysregulated expression ofmiR-34a andmiR-21 in
human and rat transplanted lungs with BOS (Table 1). Specifically, ISH analysis showed that in
normal human and rat lungs,miR-34a was diffusely expressed in bronchial and alveolar epi-
thelial cells and in some inflammatory cells, mostly plasma cells (Fig 9A). In lung explants
from BOS patients,miR-34a was strongly expressed in bronchiolar and reactive alveolar cells
and moderate expression was also detectable in proliferating fibroblasts of BO lesions (Fig 9B).
Analogously, in the rat orthotopic lung transplantation with chronic bronchiolar rejection,
miR-34a was strongly expressed in proliferating fibroblasts (Fig 9C), bronchial epithelial cells,
endothelia and inflammatory cells, mostly plasma cells, while in the setting of acute cellular
rejection,miR-34a expression was detectable only in epithelial cells and in inflammatory infil-
trates (Fig 9D).
Fig 8. Ranked list of miRNAs highly significantly enriched in a set of 39 randomly selected pathways (p<0.01) considering CMTs. Results
are plotted using a -log(p-value).
doi:10.1371/journal.pone.0161771.g008
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As far asmiR-21 was concerned, human and rat lungs with chronic bronchiolar rejection
showed strong expression in the fibroblasts of bronchiolar lesions (Fig 9E and 9G) and in epi-
thelial cells in remodeled areas, whilemiR-21 expression was not detectable in either human or
animal normal lungs. In the acute rejection animal model,miR-21 was modestly expressed in
epithelia and in interstitial fibroblasts associated with inflammatory infiltrates (Fig 9H). All
observations ofmiR-34a andmiR-21 expression were validated with alpha 1-actin and Movat
(Fig 9F) connective tissue stains on consecutive sections.
ISH results on mesenchymal cells from BAL confirmed the dysregulation observed in tissue
samples. Specifically,miR-21 was not expressed in normal fibroblasts, while it was modestly
Table 1. Profile and expression analysis ofmiR-34a andmiR-21 in human and rat lung samples: normal lung, human chronic rejection (BOS),
acute and chronic rat graft rejection.
Human CTR(1) ACUTE REJECTION(1) BOS(5)
miR-34a Bronchial and // BO fibroblasts (+++),
alveolar epithelia (++) // Reactive pneumocytes (++),
// Bronchial and alveolar epithelia (++)
miR-21 Absent // BO fibroblasts (+++),
// Reactive pneumocytes (++)
Rat CTR(2) ACUTE REJECTION(1) CHRONIC REJECTION(1)
miR-34a Bronchial and Bronchial and Reactive pneumocytes (++),
alveolar epithelia (++) alveolar epithelia (++), Fibroblasts (++),
Inflammatory infiltrates (++) Bronchial and alveolar epithelia (++),
Endothelia (++)
miR-21 Absent Reactive pneumocytes (+), Reactive pneumocytes (++),
Fibroblasts (++), Fibroblasts (+++)
Inflammatory infiltrates (+)
BO: bronchiolitis obliterans; (+): scarce expression; (++): moderate expression; (+++): strong expression.
doi:10.1371/journal.pone.0161771.t001
Fig 9. miR-34a andmiR-21 expression in human and rat transplanted lungs.Upper panel:miR-34a
expression in bronchial epithelial cells in normal human lung (A, blue staining), in myofibroblasts in lung
explants from a BOS patient (B), in proliferating fibroblasts in rat lungs with chronic rejection (C) and in
epithelial cells in remodeled areas in the animal model of acute cellular rejection (D). Lower panel:miR-21
ISH (E) and Movat pentachrome stains (F) highlightingmiR-21 expression in BOmyofibroblasts in lung
explants from BOS patients. The airway lumen, which can be recognized by the peripheral elastic fibers, is
totally occluded by collagen deposition and myofibroblasts (F), which were strongly positive formiR-21 (E,
blue staining). In rat lungs with chronic rejection,miR-21 expression was similarly observed in BO
myofibroblasts (G), while in acute cellular rejection,miR-21 expression was localized in epithelia and in
interstitial fibroblasts associated with inflammatory infiltrates (H).
doi:10.1371/journal.pone.0161771.g009
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expressed in BOS MCs.miR-34a expression was evident both in control cells and BOS MCs
(data not shown).
Discussion and Conclusions
In this paper we applied for the first time a complex computational pipeline to perform enrich-
ment analysis of miRNA targets in pathways involved in BOS pathogenesis. The analysis,
which started with literature mining to identify a limited set of relevant pathways and inte-
grated information from several public databases, ultimately produced a ranked panel of miR-
NAs potentially involved in BOS pathogenic process. The analysis considered the full set of
miRNAs annotated in miRBase (version 21), and applied a sequence of filtering approaches
and statistical analyses to reduce this set and rank the identified miRNAs. The full computa-
tional pipeline consulted only publicly available miRNA interaction data, and did not require
any expression data to perform its prediction. It was therefore well suited to perform a prelimi-
nary screening before conducting actual laboratory experiments.
Two different lists of miRNAs were produced: a first, smaller one, based on VMTs; and a
second, larger one, based on CMTs.
We proceeded to validate the analysis of the ranked lists of miRNAs by means of wet lab exper-
iments (ISH) on two highly-ranked miRNAs that appeared in both lists:miR-34a andmiR-21. As
stated above, they were chosen among those not yet described in the most recent literature on
BOS; and because of their presence in both lists (validated and computational factors).
Fig 10 shows the p-values obtained from the enrichment analysis of these two miRNAs
against all considered pathways. Subfigure A reports data computed with VMTs while subfi-
gure B reports data computed with CMTs. These p-values have been used to compute the
scores used to rank the miRNAs in Figs 5 and 6.
The first factor chosen for the validation phase wasmiR-34a, which ranked first in the
VMTs list (Fig 5) and eleventh in the CMTs list (Fig 6). It is an intergenic factor that has been
reported as a tumor suppressing gene, being consistently downregulated (mainly by promoter
hypermethylation) in a variety of cancer cells (breast, prostate, bladder, pancreas, kidney and
colon carcinoma, glioblastoma, myeloma, melanoma, and neuroblastoma) [48][49][50]. We
were able to document diffuse expression ofmiR-34a in bronchial and alveolar epithelial cells,
as well as in endothelial and inflammatory cells of normal adult lungs.
In lung samples obtained from BOS patients,miR-34a was clearly expressed in normal
bronchiolar, alveolar epithelia and reactive pneumocytes, but it was also expressed in
Fig 10. P-values obtained from themiRNA targets enrichment analysis formiR-34a andmiR-21
paired with all considered pathways. The color scale indicates the significance of the enrichment
(green = significant enrichment). A: analysis with VMTs; B: analysis with CMTs.
doi:10.1371/journal.pone.0161771.g010
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proliferating fibroblasts, suggesting that its dysregulated expression might play a role in the
fibrogenic process of BOS.
Published evidence of a profibrogenic role ofmiR-34a and of its expression by proliferating
fibroblasts is however very limited. It has been reported as being upregulated in macrophages
in the bleomycin model of pulmonary fibrosis [51] and it has been shown to play a critical role
in the progression of cardiac tissue fibrosis, mainly by targeting the TGF-beta/SMAD signal
transduction pathway [52].
Recently,miR-34a andmiR-34c have been shown able to down regulate peroxisome prolif-
erator-activated receptor (PPAR) in hepatic stellate cells thus inducing their activation, a hall-
mark of liver fibrosis [53]. PPAR has, on the other hand, been recognized as a relevant anti-
fibrotic mediator (mainly by inducing the inhibition of TGF-beta/SMAD signal transduction
pathway), thus its down regulation might be important in driving fibroblast proliferation and
extracellular matrix deposition, as recently suggested in an investigation of systemic sclerosis-
associated skin and lung fibrosis [54]. Further data are required to clarify the molecular mecha-
nisms underlying the pro-fibrotic role ofmiR-34a in BOS that we suggest in this study.
The second factor,miR-21 ranked twenty-second in the VMTs list (Fig 5) and fifteenth in
the CMTs list (Fig 6).
Interestingly, our ISH results revealed a net overexpression ofmiR-21 in BO lesions: it was
primarily expressed in fibroblasts and in activated epithelial cells in all human BOS cases and
in rat grafts, while it was completely absent in normal human and rat lungs, thus clearly dem-
onstrating upregulation in BO. Literature data in support of role ofmiR-21 in fibrogenesis are
more consistent. It was found to be significantly upregulated in the lung tissue of animal mod-
els of bleomycin-induced pulmonary fibrosis [55]; and upregulated 2.7-fold by RT PCR in a
mouse model of orthotopic tracheal transplantation [4]. In addition,miR-21 upregulation has
been demonstrated in fibroblast foci as well as in the serum of patients with idiopathic pulmo-
nary fibrosis, with a significant correlation between serum levels and the degree of lung func-
tion impairment [56]. Besides its involvement in fibro-proliferative processes in several organs
[54][56][57][58][59][60][61],miR-21 has been shown to play an important role in several
other physiological and pathological processes [62]. Its up-regulation has been observed in
solid tumors (breast, colon, lung, pancreas, prostate and stomach, ovarian, cervical, head and
neck carcinomas), in leukemias and in a variety of other human proliferative disorders, imply-
ing a function in regulating cell growth [62].
The maturemiR-21 sequence is strongly conserved throughout evolution and is encoded by
a single intergenic gene located on the plus strand of chromosome 17q23.2, where it overlaps
with the protein-coding gene VMP1. Its transcription is under the control of AP-1, SRF, p53,
Signal Transducer and Activator of Transcription 3 (STAT3) and many other TFs, as well as of
epigenetic mechanisms [62]. It is also controlled at the post-transcriptional level by: TGF-beta
and BMP via SMAD1/5 and SMAD2/3. Since the latter signaling pathway is important in epi-
thelial-mesenchymal transition (EMT), it is reasonable to think thatmiR-21 plays a role in this
process [62]. Moreover, hypoxia, which is a well-recognized stimulus for EMT [63], is a potent
miR-21 inducer. Indeed, an HIF-1alpha binding site is present in the pri-miR-21 promoter
[64].miR-21 targets several factors responsible for cell growth and invasion suppression, cell
cycle arrest, MMP and other protease inhibition, control of angiogenesis, cellular branching
and migration, with a variety of regulatory feedback loops [62]. Their down-regulation has
been reported in several cancers in whichmiR-21 is overexpressed [62]. Finally,miR-21 dysre-
gulation has been demonstrated in bio-fluids [65][66] and anti-miR-21 has been used as tar-
geted therapy in cancer, obtaining promising results both in vitro and in vivo [67,68].
On the basis of our novel finding and of previous evidence of the role ofmiR-21 in homeo-
stasis and disease, its contribution to BOS pathogenesis can be inferred to be at the level of
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myofibroblast migration and proliferation in the airway lumen, while a possible additional reg-
ulatory activity in the mechanism of epithelial-mesenchymal transition cannot be excluded.
Overall, this is the first study to systematically analyze and score a large number of miRNAs
implicated in BOS. We were able to process all the miRNAs currently annotated in miRBase
(version 21) and, by means of a sequence of computational filtering methods, we were able to
filter them and then rank them according to their enrichment into the selected pathways.
In addition tomiR-34a andmiR-21, other miRNAs have recently been described as being
dysregulated in BOS. Two recent papers reported an integrated analysis of miRNA expression
in the mouse models of orthotopic tracheal transplantation [4] [5]. The following miRNAs,
also present in the VTMs list of Fig 5, were found by RT-PCR to be dysregulated in mouse lung
tissue:miR-21,miR-146,miR-20,miR-302,miR-19,miR-98, let-7a,miR-15a. In comparison
with lung recipients without BOS, clear dysregulation ofmiR-34a,miR-193b,miR-9 andmiR-
15a, likewise present in the VTM list in Fig 5, was also detected in peripheral mononuclear
cells obtained from BOS patients in a RT-PCR evaluation of miRNA expression by Xu at al.
[3]. Even if the above results were obtained on the one hand in animals by RT-PCR without a
comprehensive analysis of cell type-restricted expression; and on the other in humans but on a
specific peripheral inflammatory cell subset, without further confirmation on lung tissue, they
might support the validation of our pipeline. Further analyses are, however, necessary to con-
firm the role of these factors in the pathogenesis of BOS.
The main limitation of our study is that only two factors identified by our pipeline under-
went validation. However, since our wet-lab experiments were intended only to confirm the
results obtained with the computational approach, more extensive tissue analysis was beyond
the scope of the study. In addition, we chose 2 miRNAs which had never been associated with
BO in previous human studies. For these reasons, while we did demonstratemiR-34a andmiR-
21 dysregulation in fibroblasts obliterating the bronchiolar lumen, we cannot provide mecha-
nistic insights into their role in BOS pathogenesis, and these should be addressed in specifically
designed studies.
Nevertheless, the data depicted in Fig 11 are a preliminary step in this direction. This shows
a regulatory network depicting the interactions between miRNAs identified in the VMTs list in
Fig 5 and all genes identified during the initial literature search as being involved in BOS (see
S1 Table). The network was constructed using the CyTransfinder Cytoscape plugin [69]. Inter-
estingly, 17 out of the 29 identified miRNAs were involved in the regulation of 14 out of the 27
Fig 11. Gene regulatory network showing interaction betweenmiRNAs identified in the VMTs list and relevant genes implicated in BOS
as identified from the literature (see the S1 Table). The network is hierarchically organized into four levels. Brown squares: miRNA host genes
for intragenic miRNAs; red and purple rhombi: intragenic and intergenic miRNAs respectively; cyan squares TFs; green hexagons: target genes.
doi:10.1371/journal.pone.0161771.g011
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identified genes. Even more interestingly, none of the identified relations involves a direct
interaction between a miRNA and a target gene, but all are mediated through one transcription
factor introduced while processing the considered pathways. All miRNAs and genes not
included in this network involve longer chains of regulation that we could not easily recon-
struct through the CyTransfinder tool and require further investigation.
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